David T MacLaughlin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

David T MacLaughlin

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Proceedings of the National Academy of Sciences of the United States of America|October 19, 2010

Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeuticsXiaolong Wei, David Dombkowski, Katia Meirelles, et al.

International Journal of Oncology|February 21, 2012

Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancerJae Yen Song, Hyun Hee Jo, Mee Ran Kim, et al.

Nature Genetics|July 17, 2007

Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromesSibel Kantarci, Lihadh Al-Gazali, R Sean Hill, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Proceedings of the National Academy of Sciences of the United States of America|October 19, 2010

Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeuticsXiaolong Wei, David Dombkowski, Katia Meirelles, et al.

International Journal of Oncology|February 21, 2012

Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancerJae Yen Song, Hyun Hee Jo, Mee Ran Kim, et al.

Nature Genetics|July 17, 2007

Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromesSibel Kantarci, Lihadh Al-Gazali, R Sean Hill, et al.

Pageof 5